Sanofi, Zealand hit by U.S. setback for diabetes drug

Your Health Matters

Employee walks into an office of French drugmaker Sanofi in ShanghaiPARIS (Reuters) – French drugmaker Sanofi said on Thursday it would withdraw its U.S. application for diabetes treatment lixisenatide in order to wait for results from an ongoing cardiovascular patient study. The decision, which will delay the drug's launch in the world's biggest market, sent shares in Sanofi down 1.6 percent by 0720 GMT, while its smaller Danish partner Zealand Pharma dropped 20 percent. …

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave